| 5 mins | 30 mins | Hourly | Daily | Weekly |
|---|---|---|---|---|
| BUY | BUY | BUY | NEUTRAL | SELL |
| 5 mins | 30 mins | Hourly | Daily | Weekly | |
|---|---|---|---|---|---|
| MA5 | 1.63▼ | 1.61▲ | 1.61▲ | 1.58▲ | 1.69▼ |
| MA10 | 1.63▼ | 1.60▲ | 1.59▲ | 1.59▲ | 1.76▼ |
| MA20 | 1.62▲ | 1.59▲ | 1.57▲ | 1.67▼ | 1.63▼ |
| MA50 | 1.60▲ | 1.57▲ | 1.57▲ | 1.76▼ | 1.36▲ |
| MA100 | 1.58▲ | 1.57▲ | 1.61▲ | 1.60▲ | 1.25▲ |
| MA200 | 1.57▲ | 1.63▼ | 1.75▼ | 1.38▲ | 2.28▼ |
| 5 mins | 30 mins | Hourly | Daily | Weekly | |
|---|---|---|---|---|---|
| MACD | 0.000▼ | 0.004▲ | 0.009▲ | -0.004▼ | -0.026▼ |
| RSI | 59.334▲ | 64.124▲ | 61.514▲ | 45.739▼ | 51.713▲ |
| STOCH | 62.222 | 81.831▲ | 86.544▲ | 31.320 | 31.014 |
| WILL %R | -40.000 | -9.524▲ | -7.692▲ | -56.667 | -70.300 |
| CCI | 10.145 | 153.763▲ | 125.318▲ | -26.824 | -75.205 |
|
Tuesday, August 12, 2025 01:18 PM
Positive IDMC Recommendation to Continue Pivotal Phase 3 REGAL Trial of Galinpepimut-S (GPS) in AML Without Modification; Final Analysis Anticipated by Year-end 2025 –- Reported Positive Phase 2 ...
|
|
Tuesday, July 15, 2025 05:44 AM
NEW YORK, July 15, 2025 (GLOBE NEWSWIRE) -- SELLAS Life Sciences Group, Inc. (NASDAQ: SLS) (“SELLAS” or the “Company”), a late-stage clinical biopharmaceutical company focused on the ...
|
|
Monday, July 07, 2025 05:50 AM
NEW YORK, July 07, 2025 (GLOBE NEWSWIRE) -- SELLAS Life Sciences Group, Inc. (NASDAQ: SLS) (“SELLAS’’ or the “Company”), a late-stage clinical biopharmaceutical company focused on the ...
|
| date | open | high | low | close | volume |
|---|---|---|---|---|---|
| 15/08/25 | 1.55 | 1.64 | 1.53 | 1.63 | 1,307,280 |
| 14/08/25 | 1.52 | 1.60 | 1.50 | 1.55 | 1,485,294 |
| 13/08/25 | 1.62 | 1.66 | 1.52 | 1.55 | 1,868,430 |
| 12/08/25 | 1.51 | 1.61 | 1.51 | 1.61 | 1,448,878 |
| 11/08/25 | 1.60 | 1.63 | 1.53 | 1.54 | 1,823,078 |
| 08/08/25 | 1.67 | 1.67 | 1.57 | 1.58 | 1,896,687 |
| 07/08/25 | 1.57 | 1.63 | 1.56 | 1.60 | 1,530,991 |
| 06/08/25 | 1.63 | 1.63 | 1.58 | 1.59 | 799,686 |
| 05/08/25 | 1.61 | 1.66 | 1.58 | 1.62 | 1,115,277 |
| 04/08/25 | 1.665 | 1.675 | 1.58 | 1.59 | 1,502,879 |
|
|
||||
|
|
||||
|
|